Company News

Company News

  • (2021-11-05) Aimedbio’s possible first-in-class brain tumor therapeutics selected by the KDDF
  • - Aimedbio’s novel brain tumor therapeutics, P302, was selected as a government-initiated drug development program by the Korean Drug Development Fund (KDDF).

    - ‘P302’ is a first-in-class ADC therapeutics targeting a brain tumor specific fusion oncogene.

    - Aimedbio has confirmed significant tumor killing effect of ‘P302’ candidate.

    - Aimedbio utilizes patients’ genetic/clinical data and patient-derived samples in the antibody development process, resulting in higher probability of clinical success.

    Link to full news

Contact Us >>